These references, though preliminary, provide at least a partial scientific framework for the claims made
If a plan denies coverage citing that GLP-1s arent covered for obesity, families can appeal under EPSDT, the plan must evaluate medical necessity rather than blanket-deny based on drug category
How Levels offers a new approach to weight management Learn more about Levels' approach to sustainable weight management Finally, GLP-1 acts directly on your nervous system
There are no surprise tier upgrades, no insurance prior-authorization delays, and no pressure to stop therapy because of cost creep
The clinical case for long-term obesity pharmacotherapy has been strengthened by SELECT trial cardiovascular outcome data, growing insurance coverage mandates, and the demonstrated durability of weight loss maintenance in patients who remain on GLP-1 therapy
If that sounds like a fishy approach, you are right